The Food and Drug Administration is reviewing the safety of the abortion pill mifepristone, Health and Human Services Secretary Robert F. Kennedy Jr. said in a recent letter to Republican state attorneys general.

Conservatives and anti-abortion groups have criticized the drug, particularly after the Biden administration in 2023 made it possible for women to receive mifepristone via telehealth and by mail. The majority of women who terminate pregnancies do so through medication abortions.

Republican attorneys general had written to Kennedy on the matter in July, and in response, Kennedy said the FDA is taking a look at the drug's Risk Evaluation and Mitigation Strategy. Kennedy in June asked FDA Commissioner Martin Makary to " review the latest data" on the drug, an FDA spokes

See Full Page